Cerenome, Inc. (NASDAQ:CNSY) — Market Cap & Net Worth
Market Cap & Net Worth: Cerenome, Inc. (CNSY)
Cerenome, Inc. (NASDAQ:CNSY) has a market capitalization of $13.59 Million ($13.59 Million) as of October 10, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26275 globally and #5484 in its home market, demonstrating a -4.28% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cerenome, Inc.'s stock price $1.79 by its total outstanding shares 7589625 (7.59 Million).
Cerenome, Inc. Market Cap History: 2026 to 2026
Cerenome, Inc.'s market capitalization history from 2026 to 2026. Data shows growth from $13.59 Million to $13.59 Million (0.00% CAGR). Check today's stock price for Cerenome, Inc. for real-time trading data and today's change.
Cerenome, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cerenome, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Cerenome, Inc. cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CNSY by Market Capitalization
Companies near Cerenome, Inc. in the global market cap rankings as of October 10, 2026. See Cerenome, Inc. net asset quality index to understand what proportion of total assets are financed by equity.
Key companies related to Cerenome, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $127.55 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $74.80 Billion USD.
- CSL Ltd (AU:CSL): Ranked #450 globally with a market cap of $62.29 Billion USD ( AU$88.04 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $127.55 Billion | $503.25 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $739.57 |
| #450 | CSL Ltd | AU:CSL | $62.29 Billion | AU$181.46 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $197.00 |
Cerenome, Inc. Historical Marketcap From 2026 to 2026
Between 2026 and today, Cerenome, Inc.'s market cap moved from $13.59 Million to $ 13.59 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $13.59 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 9th, 2026 the market cap of Cerenome, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.59 Million USD |
| MoneyControl | $13.59 Million USD |
| MarketWatch | $13.59 Million USD |
| marketcap.company | $13.59 Million USD |
| Reuters | $13.59 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cerenome, Inc.
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cance… Read more